Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.

作者
Jörge E. Cortes,Hagop M. Kantarjian
出处
期刊:PubMed [National Institutes of Health]
卷期号:6 Suppl 2: S22-S30 被引量:8
链接
标识
摘要

The development of imatinib has changed the management of chronic myeloid leukemia (CML), producing high response rates in most patients. However, most individuals treated with imatinib, 400 mg, have residual molecular disease, and both intrinsic and acquired resistance can occur. The newer tyrosine kinase inhibitors, dasatinib and nilotinib, are effective in patients with imatinib-resistant CML, In patients with relapse or resistance, current guidelines recommend escalating the dose of imatinib or switching to new tyrosine kinase inhibitors. Dasatinib has been investigated in patients who were resistant or intolerant to imatinib. Switching to dasatinib, 70 mg, twice daily has been shown to be more effective than high-dose imatinib. Another study found that dasatinib, 100 mg, once daily was just as effective as the twice-daily regimen but was better tolerated. Nilotinib is also effective in most patients with resistance or intolerance to imatinib and is associated with minimal toxicity. Other inhibitors, such as bosutinib and INNO-406, are being developed with favorable early results. New drugs are still needed, particularly for individuals who are resistant to tyrosine kinase inhibitors or those with the T3151 mutation. Emerging CML therapies, some of which have different mechanisms of action from those of tyrosine kinase inhibitors, have shown promising results and could offer an alternative to these patients as monotherapy or in combination.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
今后的应助被牧百川采纳,获得10
1秒前
高贵代芹完成签到,获得积分10
2秒前
dmq完成签到 ,获得积分10
3秒前
4秒前
方方完成签到,获得积分10
5秒前
5秒前
Happy完成签到,获得积分10
5秒前
107完成签到,获得积分10
5秒前
无极微光的应助被浮云采纳,获得20
6秒前
7秒前
henry关注了科研通微信公众号
7秒前
7秒前
一一发布了新的文献求助10
9秒前
打打的应助被南浔采纳,获得10
9秒前
9秒前
Yaaxin完成签到,获得积分20
9秒前
10秒前
耳东发布了新的文献求助150
11秒前
111发布了新的文献求助10
11秒前
molihuakai的应助被Zoey采纳,获得10
11秒前
yeting完成签到,获得积分10
12秒前
南歪歪发布了新的文献求助10
12秒前
爱文献完成签到 ,获得积分10
14秒前
wx发布了新的文献求助10
14秒前
Nole的应助被王浩采纳,获得10
15秒前
Nole的应助被王浩采纳,获得10
15秒前
车车完成签到,获得积分10
15秒前
遂安完成签到,获得积分10
16秒前
时尚朋友发布了新的文献求助10
16秒前
感动书双完成签到,获得积分10
16秒前
韩韩完成签到,获得积分20
17秒前
ding的应助被XZM采纳,获得10
17秒前
17秒前
科目三的应助被00hello00采纳,获得10
17秒前
WilliamsR1123的应助被李建勋采纳,获得10
18秒前
苗条梨愁发布了新的文献求助50
19秒前
儒雅一凤发布了新的文献求助10
19秒前
一一完成签到,获得积分10
19秒前
小跑阿甘完成签到 ,获得积分10
20秒前
哈哈怪的应助被缪缪拿铁采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183923
求助须知:如何正确求助?哪些是违规求助? 9573132
关于积分的说明 21829461
捐赠科研通 7781024
什么是DOI,文献DOI怎么找? 3434150
关于科研通互助平台的介绍 2558333
邀请新用户注册赠送积分活动 2480648